The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice
G
G
Multiple Sclerosis Clinic, University of Western Ontario, London, Ontario, Canada N6A 5A5.
D000276:Adjuvants, Immunologic / Q000191:economics / Q000627:therapeutic use; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D015415:Biomarkers; D002986:Clinical Trials as Topic; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D009500:Neutralization Tests; D017211:Treatment Failure; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000906:Antibodies; D015415:Biomarkers; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a